Idiopathic pulmonary fibrosis is the progressive parenchymal scarring & loss of pulmonary function due to unidentifiable cause of lung injury.

It is a specific form of chronic fibrosing interstitial pneumonia with the histopathologic characteristics of usual interstitial pneumonia.

Approximately 5% of patients are asymptomatic. Common signs and symptoms are exertional dyspnea, nonproductive cough, finger clubbing and bilateral inspiratory crackles.

Idiopathic%20pulmonary%20fibrosis Signs and Symptoms


  • The most common type of idiopathic interstitial pneumonia (IIP)
  • The most common interstitial lung disease among referrals & 2nd most common diagnosis or frequent disease for lung transplantation


  • A specific form of chronic, progressive fibrosing interstitial pneumonia that occurs spontaneously & is limited to the lungs, associated with a pattern of usual interstitial pneumonia (UIP) both on high-resolution computed tomography (HRCT) or lung biopsy
  • Also known as cryptogenic fibrosing alveolitis (CFA)


  • Exposure to agents like smoke, environmental pollutants & dust, viral infections, gastroesophageal reflux disease (GERD) & chronic aspiration may lead to initial alveolar epithelial damage especially in susceptible hosts
  • Familial pulmonary fibrosis (FPF)
    • Account for <5% of the total number of patients with idiopathic pulmonary fibrosis
    • May affect ≥2 family members of the same primary biological family
    • May be caused by a genetic mutation in serum surfactant protein C or A2 (SFTPA2)
    • Also associated with the gene encoding mucin 5B (MUC5B) & mutant human telomerase RNA
  • Respiratory viruses
    • Common cause of acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF)

Signs and Symptoms

  • Exertional dyspnea
  • Nonproductive cough
  • Finger clubbing
  • Bilateral inspiratory crackles
  • Systemic symptoms (arthralgia, fatigue, low-grade fever, myalgia, weight loss)
  • Exertional dyspnea & nonproductive cough are the 2 most common presenting symptoms in patients with idiopathic pulmonary fibrosis
    • Dyspnea is the most prominent symptom
  • Symptoms are nonspecific as it may present in patients with cardiac & pulmonary disease
  • Approximately 5% of the patients are asymptomatic
    • Asymptomatic patients develop their symptoms approximately 1000 days after the diagnosis of idiopathic pulmonary fibrosis on routine chest radiograph & usual interstitial pneumonia on lung biopsy 
  • It would take about 1-2 years (median duration of symptoms) before a diagnosis of idiopathic pulmonary fibrosis is established

Risk Factors

  • Cigarette smoking
  • Environmental exposure to metal dust (brass, lead, steel) & wood dust
  • Occupational exposure (farming, livestock, salon waste, stone cutting/polishing, vegetable dust)
  • Infections (Epstein-Barr virus, Hepatitis C, cytomegalovirus)
  • Gastroesophageal reflux disease via microaspiration
  • Familial pulmonary fibrosis
    • Further studies are needed to prove the association of the genetic polymorphisms for cytokines, enzymes, profibrotic molecules, coagulation pathway genes, surfactant protein-A & -B, immunomodulatory genes, & matrix metalloproteinase & idiopathic pulmonary fibrosis


  • Prevalence & incidence rates of idiopathic pulmonary fibrosis varies & depends on:
    • Ascertainment
    • Methods of reporting
    • Age
      • Incidence increases as the age advances especially on the 6th & 7th decade of life
      • Rarely seen in patients <50 years old
    • Geographic location of the population
  • Cases are higher in men than in women



  • Characteristic histopathologic features of usual interstitial pneumonia include:
    • Presence of abnormal proliferation of mesenchymal cells
    • Varying degrees of fibrosis
    • Overproduction & disorganized disposition of collagen & extracellular matrix
    • Honeycomb cysts
  • The histological hallmark of usual interstitial pneumonia is the presence of a subepithelial fibroblast foci
  • Inflammation, aberrant fibroblast & epithelial cell function, or abnormal epithelial-mesenchymal interactions with little or without an inflammatory component may play a role in the development of fibrosis in idiopathic pulmonary fibrosis
  • The initiation & perpetuation of a fibrotic response, which is considered a trigger for the development of idiopathic pulmonary fibrosis, will depend on:
    • Genetic factors
    • Environmental triggers
    • Imbalance of oxidants & anti-oxidants
    • Imbalance of Th1 & Th2 cell-derived cytokines
  • Marked proliferation of type II epithelial cells & loss of type 1 epithelial cells may be present
  • Serum concentrations of lung surfactant proteins SP-A & SP-D, & Kerbs von Lungren 6 antigen (KL-6) are increased in patients with idiopathic pulmonary fibrosis
    • A change in the concentration of KL-6 may be used as a marker for the activity of the disease
  • Abnormalities of the alveolar epithelium cells (AECs) causing altered reepithelization in idiopathic pulmonary fibrosis  patients include loss of type 1 epithelial cells, proliferation of type 2 epithelial cells, & impaired regenerative capacity of the epithelium
    • On electron microscopy, the space between the alveolar epithelium & capillary endothelium is where the resident mesenchymal cells are located
  • Excess collagen deposition within the extracellular matrix that may be due to decreased collagenolytic activity prevents re-expansion of collapse lung tissue
  • Recurring lung tissue injury & TNF-alpha gene polymorphisms have been linked to excessive collagen synthesis
  • Cytokines & growth factors that stimulates fibroblast proliferation & matrix synthesis include resident epithelial cells, endothelial cells & fibroblasts located within the lungs
  • TNF-α may be increased in patients with idiopathic pulmonary fibrosis but its role in idiopathic pulmonary fibrosis is not clear
  • Overexpressed molecules from a lung tissue or blood sample include:
    • Fibrotic cytokines
    • Matrix metalloprotein (MMP-7 & MMP-1)
    • Surfactant protein A1
    • Cyclin A2 (CCNA2)
    • Alpha-defensins
  • Gamma interferon is deficient in patients with idiopathic pulmonary fibrosis

Genetic Factors

  • Several gene mutations that may possibly play a role in the development of idiopathic pulmonary fibrosis:
    • Mutation surfactant proteins A2 (SP-A2) & C (SFTPC)
    • Risk locus for chromosome 11
    • Telomerase gene mutations (eg TERT, TERC, DKC1, TNF-2)
    • In patients with fibrotic idiopathic interstitial pneumonias, association with TERT, MUC5B & TERC telomerase gene 3q26 were confirmed
      • Other associated genes: Loci FAM13A (4q22), DSP (6p24), OBFC1 (10q24), ATP11A (13q34), DPP9 (19p13), & chromosomal regions 7q22 & 15q14-15
      • TOLLIP & SPPL2C are additional genes that were recently identified & both are associated with disease susceptibility
    • In patients with familial interstitial pneumonia (FIP), regulator of telomere elongation helicase 1 (RTEL 1) gene (rare variant), a DNA helicase that regulates the stability & replication of a telomere, were identified
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
21 Nov 2020
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
Pearl Toh, 19 Dec 2020
With the release of the latest interim efficacy results for ChAdOx1 nCoV-19, the adenovirus-vectored vaccine against COVID-19 is inching a step closer towards regulatory approval — and eventually, widespread use that will hopefully put an end to the relentless carnage by the pandemic.
Elvira Manzano, 12 Dec 2020
Having asthma or allergy does not make COVID-19 severe, a new study presented at ACAAI 2020 has shown.
Elvira Manzano, 04 Aug 2020
The global race for a COVID-19 vaccine moves at an unprecedented speed, buoyed by public pressure and geopolitical crosscurrents that were punctuated by deaths and infections around the world.